Mark Hinds
Mark Hinds
Zugehörigkeit unbekannt
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen, SN Willis, A Wei, BJ Smith, JI Fletcher, MG Hinds, PM Colman, ...
Molecular cell 17 (3), 393-403, 2005
Structural insights into the degradation of Mcl-1 induced by BH3 domains
PE Czabotar, EF Lee, MF van Delft, CL Day, BJ Smith, DCS Huang, ...
Proceedings of the National Academy of Sciences 104 (15), 6217-6222, 2007
Structure of the Alzheimer's disease amyloid precursor protein copper binding domain: a regulator of neuronal copper homeostasis
KJ Barnham, WJ McKinstry, G Multhaup, D Galatis, CJ Morton, CC Curtain, ...
Journal of Biological Chemistry 278 (19), 17401-17407, 2003
The Bcl-2-regulated apoptotic pathway
S Willis, CL Day, MG Hinds, DCS Huang
Journal of cell science 116 (20), 4053-4056, 2003
Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands
CL Day, L Chen, SJ Richardson, PJ Harrison, DCS Huang, MG Hinds
Journal of Biological Chemistry 280 (6), 4738-4744, 2005
Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat
MG Hinds, RS Norton, DL Vaux, CL Day
Nature structural biology 6 (7), 648-651, 1999
Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets
MG Hinds, C Smits, R Fredericks-Short, JM Risk, M Bailey, DCS Huang, ...
Cell Death & Differentiation 14 (1), 128-136, 2007
Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1
CL Day, C Smits, FC Fan, EF Lee, WD Fairlie, MG Hinds
Journal of molecular biology 380 (5), 958-971, 2008
The structure of Bcl‐w reveals a role for the C‐terminal residues in modulating biological activity
MG Hinds, M Lackmann, GL Skea, PJ Harrison, DCS Huang, CL Day
The EMBO journal, 2003
The Bcl-2 family: structures, interactions and targets for drug discovery
M Kvansakul, MG Hinds
Apoptosis 20, 136-150, 2015
Solution structure of the eukaryotic pore-forming cytolysin equinatoxin II: implications for pore formation
MG Hinds, W Zhang, G Anderluh, PE Hansen, RS Norton
Journal of molecular biology 315 (5), 1219-1229, 2002
Structural biology of the Bcl-2 family and its mimicry by viral proteins
M Kvansakul, MG Hinds
Cell death & disease 4 (11), e909-e909, 2013
Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity
J Wilson-Annan, LA O'Reilly, SA Crawford, G Hausmann, JG Beaumont, ...
The Journal of cell biology 162 (5), 877-888, 2003
Synthesis, conformational properties, and antibody recognition of peptides containing. beta.-turn mimetics based on. alpha.-alkylproline derivatives
MG Hinds, JH Welsh, DM Brennand, J Fisher, MJ Glennie, NGJ Richards, ...
Journal of medicinal chemistry 34 (6), 1777-1789, 1991
CARD-mediated autoinhibition of cIAP1's E3 ligase activity suppresses cell proliferation and migration
J Lopez, SW John, T Tenev, GJP Rautureau, MG Hinds, F Francalanci, ...
Molecular cell 42 (5), 569-583, 2011
Structural plasticity underpins promiscuous binding of the prosurvival protein A1
C Smits, PE Czabotar, MG Hinds, CL Day
Structure 16 (5), 818-829, 2008
Stabilization of neurotoxic soluble β-sheet-rich conformations of the Alzheimer's disease amyloid-β peptide
DJ Tew, SP Bottomley, DP Smith, GD Ciccotosto, J Babon, MG Hinds, ...
Biophysical journal 94 (7), 2752-2766, 2008
The Bcl-2 family: ancient origins, conserved structures, and divergent mechanisms
S Banjara, CD Suraweera, MG Hinds, M Kvansakul
Biomolecules 10 (1), 128, 2020
Structure of Domain III of the Blood-stage Malaria Vaccine Candidate, Plasmodium falciparum Apical Membrane Antigen 1 (AMA1)
M Nair, MG Hinds, AM Coley, AN Hodder, M Foley, RF Anders, RS Norton
Journal of molecular biology 322 (4), 741-753, 2002
The Bcl-2 family in host-virus interactions
M Kvansakul, S Caria, MG Hinds
Viruses 9 (10), 290, 2017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20